Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated Dec. 1, 2024:
Effective Jan. 1, 2025:
- Biologic Immunomodulators
- Efgartigimod
- Empaveli
- Enspryng
- Fabhalta
- Filsuvez
- HCPA MS
- Hereditary Angioedema
- Niktivmo
- Parathyroid Hormone Analog for Osteoporosis
- PCSK9
- Peanut Allergy
- Rystiggo
- Rytelo
- SA Oncology
- Soliris and Ultomiris
- Topical Estrogen
- Voydeya
- Vyjuvek
- Zepsosia
- Zilbrysq
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.